Talk:Tofacitinib
Add topicLatest comment: 8 years ago by Anypodetos in topic Still needs update?
| This is the talk page for discussing improvements to the Tofacitinib article. This is not a forum for general discussion of the subject of the article. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Tofacitinib.
|
Deletion of alopecia content seems excessive
[edit][deletion of alopecia content] seems excessive if the content is supported by the sources ? Any objections or conditions to adding back ? - Rod57 (talk) 22:47, 30 January 2016 (UTC)
FDA approved for psoriatic arthritis
[edit]Tofacitinib for PsA: From Phase III to Approval - In mid-December, tofacitinib was approved for use in active psoriatic arthritis says FDA approved it for psoriatic arthritis in Dec 2017. - Rod57 (talk) 12:43, 29 December 2017 (UTC)
Still needs update?
[edit]Anyone know what the February 2017 update request was about, and whether it was fulfilled or not? Myoglobin (talk) 17:15, 24 January 2018 (UTC)
- Not sure why this tag was added, but as tofacitinib is approved now, it should contain information about contraindications, interactions, pharmacokinetics, and probably a more extensive side effects section (see MOS:MED#Drugs, treatments, and devices). Some long-term editors would also argue for removing information about (phase 2) studies. Also, the article seems to say that the drug isn't approved in the EU, which isn't true now . --ἀνυπόδητος (talk) 18:39, 24 January 2018 (UTC)